Tainan City, Taiwan, Dec. 30, 2025 — Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology firm specializing in the development and commercialization of innovative biomedical products for precision medicine and advanced diagnostics, today revealed that on December 23, 2025, it signed an agreement (the “Agreement”) with an unrelated third party, Wei Ha Hui (the “Buyer”). Under this Agreement, the Company agreed to sell 100% of the issued and outstanding shares of Advanced Biomed (HK) Limited—a Hong Kong-based entity and fully owned subsidiary of the Company (the “Hong Kong Subsidiary”)—for a total purchase price of US$23,000. This price is based on a valuation report commissioned by the Company and is subject to the terms and conditions outlined in the Agreement.
All intellectual property held by the Hong Kong Subsidiary, including that owned by Shanghai Sglcell Biotech Co., Ltd. (a wholly owned subsidiary of the Hong Kong Subsidiary), was transferred to the Buyer upon the closing of the transaction on December 23, 2025.
Dr. Yi Lu, the Company’s CEO, stated: “Given the evolving regulatory requirements for clinical trials and data in China, and to accelerate the development and commercialization of our products and solutions, we decided to divest the assets of our Hong Kong and Shanghai subsidiaries. Moving forward, all clinical trials will be centralized and conducted through our Taiwan subsidiary, which we view as a key part of our strategic realignment.”
About Advanced Biomed Inc.
Advanced Biomed Inc. is a Nevada corporation that specializes in cutting-edge biomedical technologies for cancer detection and precision medicine.
Operating through its Taiwan subsidiary, the Company has developed a proprietary microfluidic platform that integrates semiconductor and biotechnology to enable advanced circulating tumor cell (CTC) detection, enrichment, and analysis. Its product portfolio includes devices, biochips, and solutions designed for cancer screening, diagnosis, treatment selection, and prognosis assessment. Regulatory clearances are currently in progress in Taiwan, with plans for future global expansion.
For more information, please visit: .
Forward‑Looking Statements
This press release contains forward-looking statements. These statements include discussions of plans, objectives, goals, strategies, future events or performance, underlying assumptions, and other statements that are not based on historical facts. When the Company uses terms such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” or “estimate”—or similar expressions that do not relate solely to past events—it is making forward-looking statements.
Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially from the Company’s expectations outlined in these statements. These statements are subject to uncertainties and risks, including but not limited to market conditions and other factors detailed in the documents filed with the U.S. Securities and Exchange Commission (the “SEC”). For these reasons and others, investors are cautioned not to place undue reliance on any forward-looking statements in this press release.
Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date of this release.
For more information, please contact:
Advanced Biomed Inc.
Steven I-Fang Cheng
Email:
